Ledger.Open graph →
SEC Form D · filed February 11, 2015

Lysosomal Therapeutics, Inc

Offering
$20.0M
Sold
$10.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (19)

Steven E. Hall · Cambridge, MADirectorCarole Neuchterlein · Cambridge, MADirectorBernard Davitian · Cambridge, MADirectorDaniel Geffken · Cambridge, MAExecCornelis Been · Cambridge, MAExec · DirectorRobert Carpenter · Cambridge, MADirectorBruce L. Booth · Cambridge, MADirectorClay E. Thorp · Cambridge, MADirectorBruce L. Booth · Cambridge, MADirectorLukasz Gottwald · El Segundo, CADirectorAnabatic GP, LLC · Oak Brook, ILExecAnabatic Investment Partners, LLC · Oak Brook, ILDirector22Nw, LP · Seattle, WADirector22Nw Fund GP, LLC · Seattle, WAExec · DirectorRussell J. Matthews · Denver, CODirectorWarren J. Olsen · Denver, CODirectorDavid Bree · GEORGETOWN, GRAND CAYMAN, Cayman IslandsExec · DirectorKevin E. Harrington · Boca Raton, FLDirectorThomas E. Lynch · Boca Raton, FLDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗